Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4

Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.